Ibritumomab tiuxetan
Zevalin is an antibody carrying a radioactive isotope that seeks out CD20 on lymphoma cells. It treats follicular lymphoma that has relapsed and is given as a one-off consolidation after chemotherapy.
Overview
Ibritumomab tiuxetan was the first radioimmunotherapy approved by the FDA, in February 2002, for relapsed or refractory low-grade, follicular or transformed B-cell non-Hodgkin lymphoma including rituximab-refractory disease (Study 106-06: response in a majority of 54 rituximab-refractory patients), and in 2009 for consolidation after first-line chemotherapy in follicular lymphoma with a response (FIT trial: prolonged progression-free survival). The EU authorised Zevalin in 2004. Despite efficacy and a single-day treatment, use collapsed because of logistics between nuclear medicine and haematology, prolonged cytopenias and competition from rituximab maintenance and later agents; tositumomab (Bexxar) was discontinued in 2014. Severe cytopenias and infusion reactions carry boxed warnings.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas: how tumours escape and what closes the route · Lines of therapy.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2002 | Relapsed or refractory low-grade, follicular or transformed B-cell NHL including rituximab-refractory follicular lymphoma |
| US | 2009 | Consolidation after first-line chemotherapy in previously untreated follicular NHL |
| EU | 2004 | Rituximab-relapsed or refractory CD20-positive follicular lymphoma; first-line consolidation added 2008 |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Ibritumomab tiuxetan" OR ABSTRACT:"Ibritumomab tiuxetan" OR TITLE:"Zevalin" OR ABSTRACT:"Zevalin" OR TITLE:"Y-90 ibritumomab" OR ABSTRACT:"Y-90 ibritumomab" OR TITLE:"Zevalin therapeutic regimen" OR ABSTRACT:"Zevalin therapeutic regimen") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Ibritumomab tiuxetan, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductOfatumumab
Shares Rituximab, CD20, Monoclonal antibodies and the tag nci-list.
- ProductAlemtuzumab
Shares Monoclonal antibodies and the tag nci-list.
- ProductNecitumumab
Shares Monoclonal antibodies and the tag nci-list.
- ProductSiltuximab
Shares Monoclonal antibodies and the tag nci-list.
- ProductChlorambucil
Shares Follicular lymphoma and the tag nci-list.
- ProductPlerixafor
Shares Follicular lymphoma and the tag nci-list.
- ProductTocilizumab
Shares Monoclonal antibodies and the tag nci-list.
- ProductDenosumab
Shares Monoclonal antibodies and the tag nci-list.